HRT and cardiovascular disease

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 23, Issue 1, 2009, Pages 109-120

  Stevenson, John C ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

coronary heart disease; hormone replacement therapy; metabolic risk factors; observational studies; randomized clinical trials; stroke; vascular endothelial function; venous thrombo embolism

Indexed keywords

CONJUGATED ESTROGEN; DROSPIRENONE; DYDROGESTERONE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GLUCOSE; INSULIN; LIPID; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; NORGESTREL; PLACEBO; SEX HORMONE; SPIRONOLACTONE; TRIACYLGLYCEROL;

ANTICOAGULATION; ATHEROMA; ATHEROSCLEROSIS; BLEEDING DISORDER; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMORBIDITY; CONTINUOUS INFUSION; DRUG MEGADOSE; DRUG POTENTIATION; ESTROGEN ACTIVITY; ESTROGEN DEFICIENCY; GLUCOSE METABOLISM; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN METABOLISM; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID METABOLISM; LOW DRUG DOSE; MENOPAUSE; METABOLIC DISORDER; MONOTHERAPY; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIDE EFFECT; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOEMBOLISM;

AGE FACTORS; BLOOD GLUCOSE; CORONARY DISEASE; DIABETIC ANGIOPATHIES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LIPIDS; MENOPAUSE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; WOMEN'S HEALTH;

EID: 58249084568     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2008.10.010     Document Type: Review

References (84)

1. Yussuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. Lancet 364 (2004) 937-952
2. Stevenson J.C., Crook D., and Godsland I.F. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 98 (1993) 83-90
3. Godsland I.F., and Stevenson J.C. Insulin resistance: syndrome or tendency?. Lancet 346 (1995) 100-103
4. Walton C., Godsland I.F., Proudler A.J., et al. The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. Eur J Clin Invest 23 (1993) 466-473
5. Proudler A.J., Felton C.V., and Stevenson J.C. Ageing and the response of plasma insulin, glucose and C-peptide concentrations to intravenous glucose in postmenopausal women. Clin Sci 83 (1992) 489-494
6. Ley C.J., Lees B., and Stevenson J.C. Sex- and menopause-associated changes in body-fat distribution. Am J Clin Nutr 55 (1992) 950-954
7. Spencer C.P., Godsland I.F., and Stevenson J.C. Is there a menopausal metabolic syndrome?. Gynaecol Endocrinol 11 (1997) 341-355
8. Winkler U.H. Menopause, hormone replacement therapy and cardiovascular disease: a review of haemostaseological findings. Fibrinolysis 6 Suppl. 3 (1992) 5-10
9. Lieberman E.H., Gerhard M.D., Uehata A., et al. Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. Am J Cardiol 78 (1996) 1210-1214
10. Blann A.D., Amiral J., and McCollum C.N. Circulating endothelial cell/leucocyte adhesion molecules in ischaemic heart disease. Br J Haematol 95 (1996) 263-265
11. Hwang S.J., Ballantyne C.M., Sharrett A.R., et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 96 (1997) 4219-4225
12. Zeitler H., Ko Y., Zimmermann C., et al. Elevated serum concentrations of soluble adhesion molecules in coronary artery disease and acute myocardial infarction. Eur J Med Res 2 (1997) 389-394
13. Løkkegaard E., Jovanovic Z., Heitmann B.L., et al. The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy. Maturitas 53 (2006) 226-233
14. Whitcroft S.I., Crook D., Marsh M.S., et al. Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations. Obstet Gynecol 84 (1994) 222-226
15. Godsland I.F. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 75 (2001) 898-915
16. van der Mooren M.J., de Graaf J., Demacker P.N., et al. Changes in the low-density lipoprotein profile during 17 beta-oestradiol-dydrogesterone therapy in postmenopausal women. Metabolism 43 (1994) 799-802
17. Stevenson J.C., Oladipo A., Manassiev N., et al. Randomised trial of effect of transdermal continuous combined HRT on cardiovascular risk markers. Br J Haematol 124 (2004) 802-808
18. Sack M.N., Rader D.J., and Cannon R.O. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 343 (1994) 269-270
19. Westerveld H.T., Kock L.A.W., van Rijn J.M., et al. 17β-estradiol improves postprandial lipid metabolism in postmenopausal women. J Clin Endocrinol Metab 80 (1995) 249-253
20. Crook D., Cust M.P., Gangar K.F., et al. Comparison of transdermal and oral estrogen/progestin hormone replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 166 (1992) 950-955
21. Stevenson J.C. Metabolic effects of the menopause and oestrogen replacement. Baillière's Clin Obstet Gynaecol (1996) 449-467
22. Stevenson J.C. Lipid metabolism. In: Genazzani AR. (Ed). Hormone replacement therapy and cardiovascular disease (2001), Parthenon Publishing, Carnforth 27-35
23. Crook D., Godsland I.F., Hull J., et al. Hormone replacement therapy with dydrogesterone and oestradiol-17β: effects on serum lipoproteins and glucose tolerance. Br J Obstet Gynaecol 104 (1997) 298-304
24. The Writing Group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273 (1995) 199-208
25. Warming L., Ravn P., Nielsen T., et al. Safety and efficacy of drospirenone used in a continuous combination with 17β-estradiol for prevention of postmenopausal osteoporosis. Climacteric 7 (2004) 103-111
26. Spencer C.P., Godsland I.F., Cooper A.J., et al. Effects of oral and transdermal 17β-estradiol with cyclical oral norethindrone actetate on insulin sensitivity, secretion, and elimination in postmenopausal women. Metabolism 49 (2000) 742-747
27. Spellacy W.N., Buhi W.C., and Birk S.A. The effects of estrogens on carbohydrate metabolism: glucose, insulin and growth hormone studies on one hundred and seventy one women ingesting premarin, mestranol and ethinyl estradiol for six months. Am J Obstet Gynecol 114 (1972) 378-392
28. Kanaya A.M., Herrington D., Vittinghoff E., et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/Progestin Replacement Study. Ann Int Med 138 (2003) 1-9
29. Godsland I.F., Gangar K.F., Walton C., et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 42 (1993) 846-853
30. Gambacciani M., Ciaponi M., Cappagli B., et al. Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women. J Clin Endocrinol Metab 82 (1997) 414-417
31. Archer D.F., Thorneycroft I.H., Foegh M., et al. Long term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 12 (2005) 716-727
32. Scarabin P.-Y., Oger E., and Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362 (2003) 428-432
33. Collins P., Flather M., Lees B., et al. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. Eur Heart J 27 (2006) 2046-2053
34. Straczek C., Oger E., de Jonage-Canonico M.B.Y., et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women. Circulation 112 (2005) 3495-3500
35. Canonico M., Plu-Bureau G., Lowe G.D.O., et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 336 (2008) 1227-1231
36. Stevenson J.C. Cardiovascular effects of estrogens. J Steroid Biochem Mol Biol 74 (2000) 387-393
37. Wingrove C.S., Garr E., Pickar J.H., et al. Effects of equine oestrogens on markers of vasoactive function in human coronary artery endothelial cells. Mol Cell Endocrinol 150 (1999) 33-37
38. Wingrove C.S., and Stevenson J.C. 17β-oestradiol inhibits stimulated endothelin release in human vascular endothelial cells. Eur J Endocrinol 137 (1997) 205-208
39. Koh K.K., Cardillo C., Bui M.N., et al. Vascular effects of estrogen and cholesterol lowering therapies in hypercholesterolemic postmenopausal women. Circulation 99 (1999) 354-360
40. Koh K.K., Bui M.N., Mincemoyer R., et al. Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal healthy women. Am J Cardiol 80 (1997) 1505-1507
41. Jiang C., Sarrel P., Lindsay D., et al. Endothelium-independent relaxation of rabbit coronary artery by 17β-oestradiol in vitro. Br J Pharmacol 104 (1991) 1033-1037
42. 2+ in guinea-pig isolated cardiac myocytes. Br J Pharmacol 106 (1992) 739-745
43. Ca channels through a cGMP-dependent mechanism. Circ Res 77 (1995) 936-942
44. Proudler A.J., Ahmed A.I.H., Crook D., et al. Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet 346 (1995) 89-90
45. Proudler A.J., Cooper A., Whitehead M.I., et al. Effect of oestrogen-only and oestrogen/progestogen replacement therapy upon circulating angiotensin I-converting enzyme activity in postmenopausal women. Clin Endocr 58 (2003) 30-35
46. Dollery C.M., McEwan J.R., and Henney A.M. Matrix metalloproteinases and cardiovascular disease. Circ Res 77 (1995) 863-868
47. Galis Z.S., Sukhova G.K., Lark M.W., et al. Increased expression of matrix metalloproteinases and matrix degradating activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94 (1994) 2493-2503
48. Wingrove C.S., Garr E., Godsland I.F., et al. 17β-oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta 1406 (1998) 169-174
49. Grodstein F., Manson J.E., Colditz G.A., et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133 (2000) 933-941
50. Grodstein F., Manson J.E., and Stampfer M.J. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study. Ann Intern Med 135 (2001) 1-8
51. Schlipak M.G., Angeja B.G., Go A.S., et al. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation 104 (2001) 2300-2309
52. Rosano G.M., Sarrel P.M., Poole-Wilson P.A., et al. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 342 (1993) 133-136
53. Alpaslan M., Shimokawa H., Kuroiwa-Matsumoto M., et al. Short-term estrogen administration ameliorates dobutamine-induced myocardial ischemia in postmenopausal women with coronary artery disease. J Am Coll Cardiol 30 (1997) 1466-1471
54. Rosano G.M., Caixeta A.M., Chierchia S., et al. Short-term anti-ischemic effect of 17β-estradiol in postmenopausal women with coronary artery disease. Circulation 96 (1997) 2837-2841
55. Webb C.M., Rosano G.M., and Collins P. Oestrogen improves exercise-induced myocardial ischaemia in women. Lancet 351 (1998) 1556-1557
56. Clarkson T.B., Anthony M.S., and Jerome C.P. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 83 (1998) 721-726
57. Adams M.R., Register T.C., Golden D.L., et al. Arterioscler Thromb Vasc Biol 17 (1997) 217-221
58. Clarkson T.B., Anthony M.S., and Morgan T.M. Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J Clin Endocrinol Metab 86 (2001) 41-47
59. Williams J.K., Anthony M.S., Honoré E.K., et al. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol 15 (1995) 827-836
60. Hodis H.N., Mack W.J., Lobo R.A., et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 135 (2001) 939-953
61. Alexandersen P., Tankó L.B., Bagger Y.Z., et al. The long term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric 9 (2006) 108-118
62. Herrington D.M., Reboussin D.M., Brosnihan B.K., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343 (2000) 522-529
63. Grodstein F., Manson J.E., and Stampfer M.J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health 15 (2006) 35-44
64. Collins P., Rosano G.M., Sarrel P.M., et al. 17β-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 92 (1995) 24-30
65. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
66. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288 (2002) 321-333
67. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 291 (2004) 1701-1712
68. Manson J.E., Hsia J., Johnson K.C., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349 (2003) 523-534
69. Lees B., and Stevenson J.C. The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17β and dydrogesterone. Osteoporosis Int 12 (2001) 251-258
70. Stevenson J.C. Critical comment on: randomized trial of estrogen and progestogen for secondary prevention of cardiovascular disease in postmenopausal women. Maturitas 31 (1998) 77
71. Clarke S.C., Kelleher J., Lloyd-Jones H., et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. Br J Obstet Gynaecol 109 (2002) 1056-1062
72. Hsia J., Langer R.D., Manson M.E., et al. Conjugated equine estrogens and coronary heart disease. Arch Intern Med 166 (2006) 357-365
73. Manson J.E., Allison M.A., Rossouw J.E., et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 365 (2007) 2591-2602
74. Rossouw J.E., Prentice R.L., Manson J.E., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297 (2007) 1465-1477
75. Hodis H.N., and Mack W.J. Postmenopausal hormone therapy in clinical perspective. Menopause 14 (2007) 944-957
76. Paganini-Hill A., Ross R.K., and Henderson B.E. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ 297 (1988) 519-522
77. Grodstein F., Manson J.E., Stampfer M.J., et al. Postmenopausal hormone therapy and stroke. Arch Intern Med 168 (2008) 861-866
78. Bath P.M.W., and Gray L.J. Association between hormone replacement therapy and subsequent stroke. BMJ 330 (2005) 342
79. Wassertheil-Smoller S., Hendrix S.L., Limacher M., et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA 289 (2003) 2673-2684
80. Hendrix S.L., Wassertheil-Smoller S., Johnson K.C., et al. Effect of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 113 (2006) 2425-2434
81. Oger E., and Scarabin P.-Y. Assessment of the risk for venous thromboembolism among users of hormone replacement therapy. Drugs Aging 14 (1999) 55-61
82. Eilertsen A.L., Qvigstad E., Andersen T.O., et al. Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. Maturitas 55 (2006) 278-287
83. Cushman M., Kuller L.H., Prentice R., et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 292 (2004) 1573-1580
84. Curb J.D., Prentice R.L., Bray P.F., et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 166 (2006) 772-780